NASDAQ: ITOSIteos Therapeutics Inc Stock
$10.57-0.42 (-3.82%)
Updated Apr 24, 2024
ITOS Price
$10.57
Fair Value Price
$7.13
Market Cap
$378.86M
52 Week Low
$8.20
52 Week High
$18.24
P/E
-3.36x
P/B
0.66x
P/S
31.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.60M
Earnings
-$112.64M
Gross Margin
100%
Operating Margin
-865.66%
Profit Margin
-894.3%
Debt to Equity
0.16
Operating Cash Flow
-$104M
Beta
1.08
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ITOS Overview
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ITOS ($10.57) is overvalued by 48.21% relative to our estimate of its Fair Value price of $7.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ITOS ($10.57) is not significantly undervalued (48.21%) relative to our estimate of its Fair Value price of $7.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ITOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ITOS due diligence checks available for Premium users.
Be the first to know about important ITOS news, forecast changes, insider trades & much more!
ITOS News
Valuation
ITOS fair value
Fair Value of ITOS stock based on Discounted Cash Flow (DCF)
Price
$10.57
Fair Value
$7.13
Overvalued by
48.21%
ITOS ($10.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ITOS ($10.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ITOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ITOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.36x
Industry
15.69x
Market
41.27x
ITOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
5.86x
ITOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ITOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.6M
Profit Margin
0%
ITOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ITOS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$667.6M
Liabilities
$92.4M
Debt to equity
0.16
ITOS's short-term assets ($550.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITOS's short-term assets ($550.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITOS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ITOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.8M
Investing
$61.6M
Financing
$307.0k
ITOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ITOS vs Biotech Stocks
Iteos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.